Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

We surveyed the performance of ponatinib, as salvage therapy, in a real-world setting of chronic phase chronic myeloid leukemia (CML-CP). Among 55 consecutive patients (median age 49 years) with relapsed/refractory CML-CP, 35 (64%) had failed ≥3 tyrosine kinase inhibitors (TKIs), 35 (64%) were pre-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmagid, Maymona G., Al-Kali, Aref, Litzow, Mark R., Begna, Kebede H., Hogan, William J., Patnaik, Mirinal S., Hashmi, Shahrukh K., Elliott, Michelle A., Alkhateeb, Hassan, Karrar, Omer S., Fleti, Farah, Elnayir, Mohammed H., Rivera, Candido E., Murthy, Hemant S., Foran, James M., Kharfan-Dabaja, Mohamed A., Badar, Talha, Viswanatha, David S., Reichard, Kaaren K., Gangat, Naseema, Tefferi, Ayalew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421909/
https://www.ncbi.nlm.nih.gov/pubmed/37567878
http://dx.doi.org/10.1038/s41408-023-00891-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421909/
https://www.ncbi.nlm.nih.gov/pubmed/37567878
http://dx.doi.org/10.1038/s41408-023-00891-x

Ejemplares similares